Steven Gannon

Filings by Steven Gannon span 2 companies, the busiest being Fusion Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. Over a trading history stretching from 16 August 2021 to 11 August 2026, the count stands at 9 filings.

The open-market side counts 4 purchases for €149k alongside 3 sales for €597k. Sales outweigh purchases by €448k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 option exercise. So far in 2026, the count stands at no purchases and 1 sale.

Half of the purchases are above €30k and half below. None of the 4 purchases we analysed coincided with buying by another insider of the same company within 30 days.

Most recently, on 13 August 2026, the filings show an open-market sale worth €555k in Xenon Pharmaceuticals Inc. The latest purchase dates back some time: it was published 1,529 days ago, on 11 August 2022. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.